Medistim

Regulatory Filings • May 8, 2020

Benefits of Medistim technology in Carotid Endarterectomy published in EJVES

Benefits of Medistim technology in Carotid Endarterectomy published in EJVES

(Oslo, 8th of May 2020) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the CIDAC (Comparison of Intra-operative Duplex Ultrasound and Angiography after Carotid Endarterectomy) study has now been published online in the European Journal of Vascular and Endovascular Surgery (EJVES).

The CIDAC study is a prospective trial comparing high-frequency ultrasound (HFUS, named IDUS in the study) and angiography in 150 patients as intraoperative completion control after removal of plaque in a neck artery, a procedure called carotid endarterectomy (CEA). The aim of a CEA procedure is to remove plaque that might become a source of embolism and cause stroke.

The study was conducted by Professor Henning Eckstein and team at the well-recognized Klinikum Rechts der Isar (Technical University of Munich), Germany. For the HFUS scan, the Medistim VeriQC device was used together with the L15 High-frequency Ultrasound Imaging Probe.

The results demonstrated that HFUS detected significantly more high-grade defects that needed revision compared to angiography, and with significantly higher interobserver reliability. The authors conclude that given the lesser invasiveness, HFUS could be considered as an alternative to angiography for intra-operative completion control in CEA.

“This study further strengthens the support of using Medistim’s ultrasound imaging device and probe for reducing the risk of stroke after CEA” says Medistim President and CEO, Kari E. Krogstad. «The advantages with the use of ultrasound rather than angiography include no exposure to x-rays or contrast agents and no dependency on more costly angiography equipment.”

View the CIDAC study here: https://doi.org/10.1016/j.ejvs.2020.02.017

About Medistim:

Medistim was established in 1984 and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.Medistim.com

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: thomas.jakobsen@medistim.com